Novavax Could Deliver 100M Covid-19 Vaccine Doses By End of Year, Says R&D Head

May.14 — Novavax Inc.’s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax’s president of research and development, speaks on “Bloomberg Technology.”

0

0